Objectives:

1. Learn the classes of new drugs active against Gram positive bacteria recently approved by the FDA

2  Learn the history and uses of the Pleuromutilin antibiotics and novel agents in this class that are in the pipeline

3 Understand the specific benefits and limitations of the newest drugs in treating MRSA infections

 

Session date: 
Monday, December 19, 2016 - 12:00pm to 1:00pm
Speaker Name: 
Michael David, MD, PhD
Location: 
UCMC C-400
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.